NASDAQ$ROIV
Roivant Sciences Ltd · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Roivant Sciences reported financial results and provided a business update.
Roivant Sciences reported a net loss of $291.3 million for the quarter ended March 31, 2022. The company had $2.1 billion in cash and cash equivalents as of March 31, 2022. VTAMA was approved by the FDA for the treatment of plaque psoriasis.
- VTAMA approved by FDA for the treatment of plaque psoriasis.
- Priovant established in partnership with Pfizer to develop brepocitinib for autoimmune diseases.
- Roivant reported $2.1B in cash and cash equivalents.
- Early discovery efforts validated with multiple collaborations.
Headline financials
Revenue & EPS history
Roivant Sciences · Revenue · Quarterly
$9.22M
Forward guidance
Roivant expects to provide updates on the commercial launch of VTAMA for psoriasis and report topline data from the Phase 3 clinical trials of VTAMA for the treatment of atopic dermatitis in the first half of calendar year 2023.
Tailwinds
- Dermavant expects to provide updates on the commercial launch of VTAMA® for psoriasis on a periodic basis
- Dermavant expects to report topline data from the Phase 3 clinical trials of VTAMA® for the treatment of atopic dermatitis in the first half of calendar year 2023
- Immunovant plans to initiate two Phase 3 trials to evaluate batoclimab for the treatment of thyroid eye disease in the second half of calendar year 2022, with topline results expected in the first half of calendar year 2025
- Immunovant also plans to initiate an additional Phase 3 trial in another indication in the second half of calendar year 2022 and announce two new indications by August 2022
- Results from the additional cohorts of the batoclimab and atorvastatin drug-drug interaction study are expected to be available by the end of calendar year 2022
Headwinds
- All product candidates referenced in this press release are investigational and subject to health authority approval.
- Actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions
- Those risks set forth in the Risk Factors section of our filings with the changing environment in which new risks emerge from time to time.
- These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
- Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+3.3%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.4%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+22.1%
Q3 2026
Best reaction
-5.5%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +14.9% | — | — | |
| Q3 2026 | +22.1% | +26.8% | +36.1% | |
| Q2 2026 | +2.6% | -1.6% | -1.8% | |
| Q1 2026 | -2.8% | +3.1% | +19.8% | |
| Q4 2025 | +6.4% | +5.9% | +7.3% | |
| Q4 2024 | -3.4% | +0.0% | -1.5% | |
| Q3 2024 | +4.1% | +6.6% | -5.9% | |
| Q2 2024 | +5.6% | +1.8% | +22.7% | |
| Q1 2024 | -5.2% | -6.1% | -3.5% | |
| Q4 2023 | +9.4% | +7.8% | +28.8% | |
| Q3 2023 | +9.7% | +8.2% | +7.8% | |
| Q2 2023 | +7.4% | -3.1% | +39.9% | |
| Q1 2023 | -5.5% | -15.3% | -15.8% | |
| Q4 2022 | -4.1% | -5.6% | -11.8% | |
| Q3 2021 | +5.1% | -3.2% | -25.4% | |
| Q3 2022 | +5.4% | -3.2% | -25.4% | |
| Q2 2022 | -2.4% | -4.8% | +6.8% | |
| Q2 2021 | -3.8% | -4.8% | +6.8% | |
| Q1 2021 | +0.1% | +0.7% | -38.7% | |
| Q1 2022 | +0.0% | +0.7% | -38.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro